Key Opinion Leader Perspectives Recent & Upcoming Data for Key HBV Pipeline Agents, 2018 Study Featuring Roche, Replicor, Spring Bank & Arbutus

| Source: Research and Markets Research and Markets

Dublin, March 01, 2019 (GLOBE NEWSWIRE) -- The "KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents" drug pipelines has been added to ResearchAndMarkets.com's offering.

This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.

Questions topics

  • Further Phase I data required for Roche's capsid inhibitor RO7049389
  • Replicor's US trial plans and transition from IV to subcutaneous REP 2139
  • Efficacy of Spring Bank's inarigivir at 100mg in the Phase II ACHIEVE trial
  • Expected role for inarigivir in HBV
  • Efficacy of Arbutus's Q2W IV ARB-1467
  • ARB-1467, TDF + Peg-IFN trial design, potential for functional cure, & regimen acceptability
  • Future development of Arbutus's next-generation RNAi therapeutic AB-729For internal use only

Key Highlights

  • Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ-6379 & ABI-H0731, with most concluding that Phase I data is insufficien
  • KOLs agree Replicor is making positive steps towards REP 2139's development, but similar efficacy & safety must be demonstrated in the US trials and for the SC formulation
  • Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our HBV key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Sept 2018

KOL data is analyzed to produce

  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts

Reasons to Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "recent & upcoming data for key HBV pipeline agents"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of HBV
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Key Topics Covered:

  1. Executive Summary
  2. Background
  3. Research Panel Composition
  4. Results & Implications
  5. Appendix

Companies Mentioned

  • Roche
  • Replicor
  • Spring Bank
  • Arbutus

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/szj9tz/key_opinion?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


            











    

        

        
Contact Data